Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (2P50AR065139-05)
Friends of FSH Research
Received: 23 July 2020
Accepted: 2 March 2021
First Online: 10 March 2021
: The study was approved by the Human Subjects Committee at Universities of Rochester and Washington, with written informed consent obtained for all participants.
: This was part of the informed consent.
: LHW reports consultancy for Biogen. KE reports consultancy for Fulcrum Therapeutics, Acceleron, Biogen, and Ionis. SDF and SJT report consultancy for Fulcrum Therapeutics. RT reports consultancy with Fulcrum Therapeutics and Acceleron Pharma. JS reports consultancy for Fulcrum Therapeutics, Acceleron, Strongbridge Biopharma, AveXis, Sarepta, PTC, and Expansion.